OMEICOS Therapeutics GmbH - AF

Irregular heart rhythm

Atrial fibrillation (AF) is the most common cardiac arrhythmia in humans. AF presents as an irregular, often very fast rhythm, originating from the heart's upper chambers. As a consequence, heart chambers pump the blood inefficiently, which can lead to severe instability of the blood circulation and to heart failure.

In daily life, patients with AF suffer from shortness of breath and impaired exercise capacity. The episodes of palpitations cause nervous reactions like sweating, dizziness and feelings of anxiety. Taken together these symptoms reduce significantly the Quality of Life (QoL) of AF patients. Beside the strong impact on QoL, AF also causes other, severely increased health risks for the patients. AF doubles the risk of death, increases the risk of stroke almost five fold and raises overall the risk of heart failure.

Existing anti-arrhythmic drugs only have a limited effect and are often associated with the risk of serious side effects.

The therapeutic concept of the currently available anti-arrhythmic drugs is limited to the suppression of AF. The mission of OMEICOS is to develop a safe drug that not only improves the QoL of AF patients by preventing AF episodes also provide a curative effect to the diseased heart.


In 2013, approximately 3.7 million patients in the US and 6.2 million patients in the EU are living with AF. The prevalence of AF increases with age. People older than 40 years have about a 25% chance of developing AF in their lifetime.

The market for AF drugs is expected to increase 7-fold, from USD 1.3bn in 2010 to almost USD 9bn by 2020. Within this market, the share for anti-arrhythmic drugs has been forecasted worth USD 2bn in 2020.

Limited options for drug therapy as well as high and steadily growing numbers of patients suffering from AF result in a very high unmet medical need for a safe and efficient new anti-arrhythmic drug.